Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ahmed Yahia Elmowafy"'
Autor:
Gamal Shiha, Ahmed Yahia Elmowafy, Reham Soliman, Ahmed Farouk Donia, Hanzada Mohamed El Maghrabi, Yasser Abdel-Monem El-Hendy, Mabrouk I. Ismail, Mohamed A. Bakr
Publikováno v:
Experimental and Clinical Transplantation. 17:62-67
Objectives Chronic hepatitis C infection incidence and prevalence are high in Egypt and represent a major health burden. Hepatitis C virus infection can affect graft outcomes in kidney transplant recipients. Treatment of hepatitis C virus infection a
Autor:
Sameera Sh. Hamed, Mahmoud Awad, Adel Elmansoury, Ahmed Yahia Elmowafy, Amira Emam, Sahar El-Dakroory
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Chronic kidney disease (CKD) was one of the three reasons of mortality with the furthermost increase from 1990 to 2010 between the top 20 killers. Environmental toxins (Lead Pb and Cadmium Cd) are hidden factors incorporated in th
Autor:
Salwa Mahmoud Elwasif, M.A. Bakr, Hussein Sheashaa, Ahmed Yahia Elmowafy, Gamal Shiha, Mohamed Hamed Abbas, Han Elmaghrabi, Reham Soliman, Lionel Rostaing
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims With the advance of new direct acting antiviral, treatment of HCV became safer and easier. Renal impairment makes treatment of HCV more difficult due to poor drug tolerability. Anemia is a common side effect occurring in renal pat
Autor:
Samar Elshahat, Ahmed Mohamed Naguib Attiya, Ahmed Yahia Elmowafy, Salwa Mahmoud Elwasif, Ibrahim Galalah, Ayman F. Refaie, Khaled El-Dahshan
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Vascular access remains a significant challenge for patients on chronic hemodialysis (HD) and often requires creative thinking to preserve and construct durable long-term access. While AVFs continue to remain the gold standard for
Autor:
Rasha T. Abouelkheir, Lionel Rostaing, Mohamed Hamed Abbas, Ahmed Yahia Elmowafy, M.A. Bakr, Ayman F. Refaie
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Great progression in treating hepatitis C infection has been made with the new Interferon-free regimens. Reports about developing hepatocellular carcinoma after DAAs have been spotlighted. Kidney transplantation and hemodialysis a
Autor:
Lionel Rostaing, Ahmed Yahia Elmowafy, Gamal Shiha, Mohamed Hamed Abbas, Salwa Mahmoud El Wasif, Mohamed Elsayed Mashaly, Mohamed A. Bakr, Ahmed Abdelfattah Denewar
Publikováno v:
International urology and nephrology. 53(4)
Chronic hepatitis-C infection is a great health burden in Egypt. The effect of anemia on the efficacy and safety of direct-acting anti-viral (DAA) therapies for those with chronic-kidney disease (CKD) has not been evaluated. This single-center retros
Autor:
Hanzada Mohamed El Maghrabi, M. Elbasiony, Lionel Rostaing, Gamal Shiha, Mohamed A. Bakr, Ahmed Yahia Elmowafy, Ayman F. Refaie
Publikováno v:
International urology and nephrology. 51(12)
Hepatitis C virus (HCV) infection in kidney transplant recipients (KTRs) is common and can impact on patient and graft survival rates. The efficacy and safety of direct-acting antivirals (DAAs) to treat genotype-4 HCV-infected KTRs have not been full
Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality
Autor:
Ayman F. Refaie, Khaled El-Dahshan, Mohamed A. Bakr, Yasser Elsayed Matter, Hanzada Mohamed El Maghrabi, Lionel Rostaing, Ahmed Yahia Elmowafy, Hazem Hamed Saleh, Gamal Shiha, M. Elbasiony
Publikováno v:
International urology and nephrology. 51(9)
New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV)
Autor:
Amir M Elokely, Ahmed Yahia Elmowafy, Essam Elsawy, Tamer M. Gouda, Hazem Hamed Saleh, Mahmoud H Zahran, Ahmed M. Abdel-Rahman, Ehab W. Wafa, Mohamed Kamal Ahmed Ibrahim
Publikováno v:
Journal of The Egyptian Society of Nephrology and Transplantation. 21:65
Background Variable prophylaxis regimens have been adapted to guard against cytomegalovirus (CMV) after renal transplantation. High-dose valganciclovir (VGCV) is the gold standard, but it is of very high cost. Herein, we compared another low-cost reg
Autor:
Mohamed A. Bakr, H.A. Sheashaa, Mohamed Hamed Abbas, S. El Wassif, Gamal Shiha, Reham Soliman, Ahmed Yahia Elmowafy, H.M. El Maghrabi
Publikováno v:
Kidney International Reports. 5:S127